MedTrace Logo

Search for Predictors of Therapeutic Response in Ovarian Carcinoma

NCT01391351 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 107

Last updated 2016-07-21

No results posted yet for this study

Summary

In order to search for predictors of response to chemotherapy in patients with ovarian carcinoma of the ovary, the fallopian tube or peritoneal serous-type advanced stage, we will define the comparative profiles of miRNA expression of serum polymorphisms and determine differential in 2 patient populations (with or without recurrence 6 months after completion of chemotherapy) with (i) the miRNA profile of serum before treatment and (ii) identification of polymorphisms or SNP (Single Nucleotide Polymorphism) in particular genes involved in the metabolism of chemotherapy agents In the case of miRNA, expression profiles will also be studied during the first course in response to chemotherapy. Indeed, the miRNA profile of serum may be different at baseline among the 2 types of populations (or non-recurrence at 6 months).

Conditions

Interventions

OTHER

blood samples

blood samples in patients receiving Taxol and carboplatin chemotherapy : * On Day 1 of the first course of chemotherapy * On Day 1 of the second course of chemotherapy * Before the surgery, if programmed via J1 or the fourth cycle of chemotherapy * At the end of chemotherapy

OTHER

blood samples

blood samples in patients receiving Taxol and carboplatin chemotherapy with avastin: * On Day 1 of the first course of chemotherapy * On Day 1 of the second course of chemotherapy * Before the surgery, if programmed via J1 or the fourth cycle of chemotherapy * At the end of chemotherapy

Sponsors & Collaborators

  • Centre Francois Baclesse

    lead OTHER

Principal Investigators

  • Florence JOLY-LOBBEDEZ, PD · Centre François Baclesse

  • Sophie KRIEGER, MD · Centre François Baclesse

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2015-11-30
Completion
2016-07-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01391351 on ClinicalTrials.gov